RALEIGH, N.C.–(BUSINESS WIRE)–Veranex, the first concept-to-commercialization global service provider dedicated to the medtech industry, today announced the acquisition of Experien Group, a leading provider of a full range of regulatory, quality, and clinical consulting services to medtech companies. Formed in partnership with global growth investor Summit Partners, Veranex provides the global medical technology industry integrated product development strategies and services across the product life cycle. As a result of this transaction, Veranex’s West Coast operations offer a unique, client-responsive consulting model that adjusts to meet client program requirements.
“We are excited to welcome Experien Group to Veranex,” said David Dockhorn, CEO of Veranex. “With this acquisition, Veranex adds the premier provider of regulatory, quality, and clinical consulting services to medtech companies. Veranex’s clients will benefit from Experien’s long-standing FDA engagement, well-established global regulatory guidance experience, and a demonstrated track record of successful approvals.”
“Experien Group adds another layer of value and medtech insight to Veranex,” said Veranex Executive Chairman Pat Donnelly. “We will continue to seek additional strategic acquisitions that add depth and resources to the full-service, end-to-end medtech solutions that Veranex has brought to the industry for the first time.”
Veranex combines product development, regulatory, and market access expertise — globally and across complex and emerging markets — to help clients achieve their innovation objectives, accelerating time to market and optimizing clinical adoption and patient access.
Financial terms of the transaction were not disclosed.
About Veranex
Veranex is the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry. Offering expert guidance from concept through to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its integrated and comprehensive solutions unify the entire development process. For more information, visit VeranexSolutions.com.
Contacts
Lindsey Langemeier
SCORR Marketing
402-405-4269
lindsey@scorrmarketing.com
Well-Capitalized Combined Company with Strong Financial Profile and 2023 Revenue of $246M, 28% from Recurring…
Chowis Co. Ltd. Skin, Hair and Scalp Solutions Provider Signs Agreement with Kolmar Korea to…
PORTLAND, OR / ACCESSWIRE / July 3, 2024 / Rose Villa Senior Living continues to…
Highlights:Total revenue of $9.9 million for Q1 2025, reflecting YoY growth of 31% from the…
Medical Device Developer & Investor Taps 4 Markets With Growth Projections of USD $39.1B by…
The round is led by Danish VC Dreamcraft, together with biotech investor Lundbeckfonden BioCapital and…